Because we now show that a resistant phenotype against cisplatin/pemetrexed is present before chemotherapy, we infer that intrinsic properties of the tumor, including gain of function of TP53, deletion of NF2, and CDKN2A participate to the evolution of resistant cells toward EMT. The gene discussed is NF2; the disease is neoplasm.